Matthew Gavidia

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.

Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.

Findings of a survey of large employers indicate that utilization management tools are ineffective in controlling health care costs for employees and may lead to barriers to treatment.

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of comorbidities.

Patient-reported treatment goals for psoriasis showed varied preferences according to characteristics such as age, severity, and gender, but the top goal overall was to have confidence in the therapy.

Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, discussed how new guidelines issued by the American Academy of Dermatology (AAD) regarding comorbidity risk in patients with atopic dermatitis will influence the condition's treatment.

The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.

Young adult men with chronic rhinosinusitis with nasal polyps were shown to be at greater risk of nasal polyp recurrence after endoscopic sinus surgery than elderly men and adult women of all ages.

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, explains tildrakizumab’s mechanisms of action in the treatment of psoriasis and how the drug differs from other approved biologics.

Patients with atopic dermatitis who achieved rapid changes in skin pain severity with the Janus kinase inhibitor baricitinib were associated with clinically significant improvement in Dermatology Life Quality Index scores.

Two abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting explored the health-related quality of life (QOL) and mental health impact of psoriasis disease burden by severity and affected body region.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the need for increased lung cancer screening among patients who have no tobacco use history.

A significantly greater proportion of patients with chronic rhinosinusitis with nasal polyps reported symptom-free days for at least 1 symptom when treated with dupilumab vs placebo in the 28 days preceding 24-week and 52-week analysis intervals.

Only half of pediatric patients with atopic dermatitis who fit the criteria of having severe disease were identified as such by managing physicians.

Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.

Melissa Johnson, MD, program director of lung cancer research at Sarah Cannon Research Institute, outlines the importance of diverse patient populations in cancer trials.

Orly Vardeny, PharmD, MS, core investigator, Center for Care Delivery and Outcomes Research, and associate professor of Medicine, University of Minnesota Medical School, discusses key barriers to access of novel therapies and what sessions she’s looking forward to during the American College of Cardiology's (ACC) 71st Annual Scientific Session.

Younger and older patients with noneosinophilic chronic rhinosinusitis (CRS) with nasal polyps showed significant differences in preoperative blood eosinophil levels and postoperative modified Lund-Kennedy scores.

Findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting showed that ruxolitinib cream (​​Opzelura) demonstrated significant improvement vs vehicle in patients with atopic dermatitis of Black race and across anatomic regions.

Longer drug survival was associated with interleukin-17 (IL-17) inhibitors vs tumor necrosis factor (TNF) inhibitors in the treatment of psoriasis and psoriatic arthritis, but persistence rates for first-line biologics overall remained low.

A Monday session at the 2022 American Academy of Dermatology Annual Meeting discussed strategies for risk stratification and therapeutic management of nonmelanoma skin cancers.

Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.

Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead, Rheumatology Therapeutic Area at Janssen, speaks on nontherapeutic approaches to manage symptom burden of psoriatic arthritis.

Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.

Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, explains factors inhibiting uptake of next-generation sequencing testing among patients with lung cancer.